{"id":2159,"date":"2026-07-25T08:30:00","date_gmt":"2026-07-25T12:30:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2159"},"modified":"2026-07-25T15:17:54","modified_gmt":"2026-07-25T19:17:54","slug":"most-second-line-lymphoma-patients-miss-curative-therapy","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2159","title":{"rendered":"Most Second-Line Lymphoma Patients Miss Curative Therapy"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

LEO Consortium (Lymphoma Epidemiology of Outcomes)<\/p>\n

Event Type<\/strong><\/p>\n

Peer-Reviewed Publication (Real-World Cohort Study)<\/p>\n

Platform<\/strong><\/p>\n

Autologous Stem-Cell Transplantation \/ CD19-Directed CAR-T<\/p>\n

Indication<\/strong><\/p>\n

Relapsed or Refractory Large B-Cell Lymphoma<\/p>\n

Summary<\/h4>\n

The LEO CReWE study analyzed 1,504 patients with relapsed or refractory large B-cell lymphoma treated from 2002 through 2022. Although autologous transplantation or CAR-T was planned for 65% at second line, only 31% received transplantation and 6% received CAR-T. Patients intended for curative therapy but unable to reach it had outcomes as poor as patients never intended for curative treatment. Median event-free survival from second line was 4.3 months and median overall survival was 18.3 months. The study is retrospective and spans major treatment-era changes, but it defines delivery failure \u2014 not only drug efficacy \u2014 as a central clinical problem.<\/p>\n

The multicenter cohort included 1,504 patients with relapsed or refractory large B-cell lymphoma treated between 2002 and 2022. Sixty-four percent received chemoimmunotherapy in second line.<\/p>\n

A potentially curative strategy involving autologous stem-cell transplantation and\/or CAR-T was planned for 984 patients, or 65%. Ultimately, 471 patients, or 31%, received transplantation and 94, or 6%, received CAR-T.<\/p>\n

Complete-response rates ranged from 24% with lenalidomide-based regimens to 49% with CAR-T. Salvage chemotherapy produced a 44% complete-response rate overall and 60% among patients who subsequently reached transplantation.<\/p>\n

Median event-free survival was 4.3 months and median overall survival was 18.3 months from second-line treatment. Outcomes improved in periods when CAR-T was available, but patients who failed to reach planned curative therapy fared poorly.<\/p>\n

Clinical Interpretation<\/h4>\n

The decisive signal is the gap between intent and delivery. Planning transplantation or CAR-T does not provide benefit if disease progression, toxicity, referral delay, manufacturing time, organ dysfunction, or access prevents the patient from reaching definitive therapy.<\/p>\n

The cohort supports response to bridging or salvage therapy as a selection gateway. This creates survivor and treatment-selection bias: favorable outcomes among transplanted patients partly reflect biology and fitness required to reach transplantation.<\/p>\n

Treatment-Era Context<\/h4>\n

The study begins in 2002, long before modern second-line CAR-T approvals, bispecific antibodies, polatuzumab-based therapy, and improved supportive care. Only 94 patients received CAR-T, limiting inference about present-day comparative effectiveness.<\/p>\n

Improved survival during CAR-T-available eras is encouraging but cannot be attributed solely to CAR-T because diagnostics, supportive care, referral patterns, and later-line options changed simultaneously.<\/p>\n

Access and Trial-Design Implications<\/h4>\n

Time-to-treatment and the probability of reaching infusion are clinically meaningful attributes. Trials and health systems should measure attrition between referral, leukapheresis, manufacturing, conditioning, and infusion rather than analyzing only infused patients.<\/p>\n

Off-the-shelf bispecific antibodies and rapidly deployable regimens may be valuable even if per-protocol efficacy is lower than CAR-T, because availability can rescue patients whose disease cannot wait. Comparative frameworks should include intention-to-treat delivery and not only product-treated outcomes.<\/p>\n

Competitive Implications<\/h4>\n

The data strengthen the strategic rationale for earlier-line CAR-T, decentralized delivery, faster manufacturing, vein-to-vein reliability, outpatient administration, and ready-to-use T-cell engagers.<\/p>\n

New randomized trials have shifted second-line standards for early relapse, so the cohort is better viewed as a baseline map of care failure than as a current ranking of regimens.<\/p>\n

Company and Product Background<\/h4>\n

Large B-cell lymphoma is an aggressive mature B-cell malignancy. Curative second-line approaches include autologous stem-cell transplantation after chemosensitive salvage and CD19-directed CAR-T, with selection influenced by relapse timing, biology, fitness, access, and treatment speed.<\/p>\n

The Lymphoma Epidemiology of Outcomes consortium combines prospective and retrospective data from major U.S. lymphoma centers. The CReWE analysis was supported by the National Cancer Institute and Genentech.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Scale: 1,504 second-line large B-cell lymphoma patients across two decades.<\/li>\n
  • Implementation gap: 65% had curative therapy planned, but 31% received transplantation and 6% received CAR-T.<\/li>\n
  • Poor attrition outcome: failure to reach planned curative therapy produced outcomes comparable with non-curative intent.<\/li>\n
  • System implication: speed, referral, manufacturing, bridging, and fitness preservation materially determine real-world benefit.<\/li>\n
  • Evidence boundary: historical-era and treatment-selection confounding prevent direct modern regimen ranking.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    This study changes the framing of second-line lymphoma competition. Product efficacy matters, but the operational probability of reaching definitive therapy is itself a treatment attribute and a major source of lost clinical benefit.<\/p>\n

    The modern opportunity is to shorten every interval from relapse recognition to active therapy while preserving curative options. Prospective datasets should report all referred or intended patients, not only those successfully infused or transplanted.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal strength:<\/strong> 3\/5 \u2014 Medium-High. Importance:<\/strong> Medium-High \u2014 the cohort quantifies a major real-world delivery failure in a core hematologic malignancy and informs development of faster cell-therapy and off-the-shelf strategies. Confidence:<\/strong> High for the descriptive cohort findings; medium for current comparative conclusions because most patients predated modern second-line CAR-T and treatment assignment was nonrandom.<\/p>\n","protected":false},"excerpt":{"rendered":"

    The LEO CReWE study analyzed 1,504 patients with relapsed or refractory large B-cell lymphoma treated from 2002 through 2022. Although autologous transplantation or CAR-T was planned for 65% at second line, only 31% received…<\/p>\n","protected":false},"author":1,"featured_media":2174,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,4],"tags":[130,188],"class_list":["post-2159","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-technology-modalities","tag-large-b-cell-lymphoma","tag-leo-consortium"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2159"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2159\/revisions"}],"predecessor-version":[{"id":2185,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2159\/revisions\/2185"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2174"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}